Clinical Professor of Medicine, Georgetown University School of Medicine, Pvt. Pract., Baltimore
Hematology
Dr. Michael Auerbach, MD
|
|
Give Review
Michael Auerbach is an expert in the field of Hematology. He went to New York Medical College. He over the years received 1 awards: "Super Doctor". Michael Auerbach is a published doctor. He has 40 papers published. The most current publication "Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial." He accepts Medicare.
Publications
- Is Low Molecular Weight Iron Dextran Really the Most Risky Iron - Unconvincing Data from an Unconvincing Study.
- Intravenous iron in chemotherapy-induced Anemia.
- Hypersensitivity from Intravenous Iron Products.
- Intravenous iron in inflammatory bowel disease.
- IV Iron in pregnancy: An unmet clinical need.
- Is it time for a new standard?
- Iron: The new advances in therapy.
- Oral or IV Iron in Inflammatory Bowel Disease.
- Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient Anemia.
- Ferumoxytol for the treatment of iron deficiency.
- Should intravenous iron be upfront therapy for iron deficiency Anemia?
- Clinical use of intravenous iron: administration, efficacy, and safety.
- Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced Anemia.
- Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
- Finding a safe and effective intravenous iron treatment for restless legs syndrome.
- Intravenous iron: from anathema to standard of care.
- The role of intravenous iron in Anemia management and transfusion avoidance.
- High-molecular weight iron dextran: a wolf in sheep's clothing?
- Increased importance of intravenous iron in chemotherapy-induced Anemia.
- Clinical update: intravenous iron for anaemia.
- Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related Anemia: a multicenter, open-label, randomized ...
- Intravenous iron.
- New intravenous iron replacement therapies.
- Iron replacement therapy in cancer-related Anemia.
- Anemia management and mortality risk in incident hemodialysis patients.
- Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast Cancer.
- Iron and the anaemia of chronic disease: a review and strategic recommendations.
- A randomized trial of three iron dextran infusion methods for Anemia in EPO-treated dialysis patients.
- Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.
- Intravenous iron as standard of care in oncology: opportunity lost.
- Anemia management in chronic kidney disease: intravenous iron steps forward.
- Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with Cancer receiving chemotherapy.
- Intravenous iron in oncology.
- Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced Anemia may be related to ESA induced iron restricted erythropoiesis and reversed...
- Should intravenous iron be the standard of care in oncology?
- Ferumoxytol as a new, safer, easier-to-administer intravenous iron: yes or no?
- Iron replacement therapy in cancer-related Anemia: introduction.
- Reexamination of the need for treatment in Idiopathic Thrombocytopenic Purpura.
- Safety and Efficacy of Rapid (1000 mg in one hour) Intravenous Iron Dextran for Treatment of Maternal Iron Deficient Anemia.
Schools
New York Medical College
Cleveland Clinic
Columbia Presby Med Center
Conditions Treated
- Anemia
- Bladder Cancer
- Breast Cancer
- Colorectal Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
New York Presbyterian Hospital - Columbia Campus -
Cleveland Clinic Foundation -
New York Medical College
Drug Facts
| NPI NUMBER | 1336199942 | |
| NPPES Provider LastName | AUERBACH | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 212374001 | |
| NPPES Provider State | MD | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 486.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 72.0 | |
| Percent Opioid Claims | 14.81 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1336199942 |
| Last Name Of The Provider | AUERBACH |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. John J. Strouse, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Saranya A. Chumsri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine L. Hann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey L. Seibel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mya S. Thein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin L. Maughan, MD |
|
|
Dr. Ann B. Zimrin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Cho C. Maung, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Adrian G. Murphy, MB CHB |